Academic Journal
High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity.
| Title: | High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity. |
|---|---|
| Authors: | Vazquez-Lombardi R; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland; Engimmune Therapeutics AG, Hegenheimermattweg 167A, 4123 Allschwil, Switzerland. Electronic address: rodrigo.vl@engimmune.com., Jung JS; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland., Schlatter FS; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland., Mei A; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland., Mantuano NR; Department of Biomedicine, Universitätsspital Basel, Basel, Switzerland., Bieberich F; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland., Hong KL; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland., Kucharczyk J; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland., Kapetanovic E; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland., Aznauryan E; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland., Weber CR; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland., Zippelius A; Department of Biomedicine, Universitätsspital Basel, Basel, Switzerland., Läubli H; Department of Biomedicine, Universitätsspital Basel, Basel, Switzerland., Reddy ST; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland. Electronic address: sai.reddy@ethz.ch. |
| Source: | Immunity [Immunity] 2022 Oct 11; Vol. 55 (10), pp. 1953-1966.e10. Date of Electronic Publication: 2022 Sep 28. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 9432918 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4180 (Electronic) Linking ISSN: 10747613 NLM ISO Abbreviation: Immunity Subsets: MEDLINE |
| Imprint Name(s): | Publication: Cambridge, MA : Cell Press Original Publication: Cambridge, Mass. : Cell Press, c1994- |
| MeSH Terms: | Immunotherapy, Adoptive* , Receptors, Antigen, T-Cell*, Antigens, Neoplasm ; Humans ; Immunotherapy ; Peptides |
| Abstract: | A major challenge in adoptive T cell immunotherapy is the discovery of natural T cell receptors (TCRs) with high activity and specificity to tumor antigens. Engineering synthetic TCRs for increased tumor antigen recognition is complicated by the risk of introducing cross-reactivity and by the poor correlation that can exist between binding affinity and activity of TCRs in response to antigen (peptide-MHC). Here, we developed TCR-Engine, a method combining genome editing, computational design, and deep sequencing to engineer the functional activity and specificity of TCRs on the surface of a human T cell line at high throughput. We applied TCR-Engine to successfully engineer synthetic TCRs for increased potency and specificity to a clinically relevant tumor-associated antigen (MAGE-A3) and validated their translational potential through multiple in vitro and in vivo assessments of safety and efficacy. Thus, TCR-Engine represents a valuable technology for engineering of safe and potent synthetic TCRs for immunotherapy applications. Competing Interests: Declaration of interests ETH Zurich has filed for patent protection on the technology and sequences described herein, and R.V.-L., J.S.J., and S.T.R. are named as co-inventors on this patent (WO2021074249A1). R.V.-L and S.T.R. are co-founders and hold shares of Engimmune Therapeutics AG. S.T.R. may hold shares of Alloy Therapeutics. S.T.R. is on the scientific advisory board of Engimmune Therapeutics and Alloy Therapeutics. (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.) |
| Contributed Indexing: | Keywords: T cell receptor; TCR; deep sequencing; immunotherapy; protein engineering |
| Substance Nomenclature: | 0 (Antigens, Neoplasm) 0 (Peptides) 0 (Receptors, Antigen, T-Cell) |
| Entry Date(s): | Date Created: 20220929 Date Completed: 20221014 Latest Revision: 20221018 |
| Update Code: | 20221216 |
| DOI: | 10.1016/j.immuni.2022.09.004 |
| PMID: | 36174557 |
| Database: | MEDLINE |
| ResultId |
1 |
|---|---|
| Header |
cmedm MEDLINE 36174557 3 Academic Journal academicJournal |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=36174557 |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity.
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AU" term="%22Vazquez-Lombardi+R%22">Vazquez-Lombardi R</searchLink>; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland; Engimmune Therapeutics AG, Hegenheimermattweg 167A, 4123 Allschwil, Switzerland. Electronic address: rodrigo.vl@engimmune.com.<br /><searchLink fieldCode="AU" term="%22Jung+JS%22">Jung JS</searchLink>; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Schlatter+FS%22">Schlatter FS</searchLink>; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Mei+A%22">Mei A</searchLink>; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Mantuano+NR%22">Mantuano NR</searchLink>; Department of Biomedicine, Universitätsspital Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Bieberich+F%22">Bieberich F</searchLink>; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Hong+KL%22">Hong KL</searchLink>; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kucharczyk+J%22">Kucharczyk J</searchLink>; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kapetanovic+E%22">Kapetanovic E</searchLink>; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Aznauryan+E%22">Aznauryan E</searchLink>; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Weber+CR%22">Weber CR</searchLink>; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Zippelius+A%22">Zippelius A</searchLink>; Department of Biomedicine, Universitätsspital Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Läubli+H%22">Läubli H</searchLink>; Department of Biomedicine, Universitätsspital Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Reddy+ST%22">Reddy ST</searchLink>; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland. Electronic address: sai.reddy@ethz.ch. ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <searchLink fieldCode="JN" term="%229432918%22">Immunity</searchLink> [Immunity] 2022 Oct 11; Vol. 55 (10), pp. 1953-1966.e10. <i>Date of Electronic Publication: </i>2022 Sep 28. ) Array ( [Name] => TypePub [Label] => Publication Type [Group] => TypPub [Data] => Journal Article; Research Support, Non-U.S. Gov't ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => TitleSource [Label] => Journal Info [Group] => Src [Data] => <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9432918 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-4180 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210747613%22">10747613 </searchLink><i>NLM ISO Abbreviation: </i>Immunity <i>Subsets: </i>MEDLINE ) Array ( [Name] => PublisherInfo [Label] => Imprint Name(s) [Group] => PubInfo [Data] => <i>Publication</i>: Cambridge, MA : Cell Press<br /><i>Original Publication</i>: Cambridge, Mass. : Cell Press, c1994- ) Array ( [Name] => SubjectMESH [Label] => MeSH Terms [Group] => Su [Data] => <searchLink fieldCode="MM" term="%22Immunotherapy%2C+Adoptive%22">Immunotherapy, Adoptive*</searchLink> <br /><searchLink fieldCode="MM" term="%22Receptors%2C+Antigen%2C+T-Cell%22">Receptors, Antigen, T-Cell*</searchLink><br /><searchLink fieldCode="MH" term="%22Antigens%2C+Neoplasm%22">Antigens, Neoplasm</searchLink> ; <searchLink fieldCode="MH" term="%22Humans%22">Humans</searchLink> ; <searchLink fieldCode="MH" term="%22Immunotherapy%22">Immunotherapy</searchLink> ; <searchLink fieldCode="MH" term="%22Peptides%22">Peptides</searchLink> ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => A major challenge in adoptive T cell immunotherapy is the discovery of natural T cell receptors (TCRs) with high activity and specificity to tumor antigens. Engineering synthetic TCRs for increased tumor antigen recognition is complicated by the risk of introducing cross-reactivity and by the poor correlation that can exist between binding affinity and activity of TCRs in response to antigen (peptide-MHC). Here, we developed TCR-Engine, a method combining genome editing, computational design, and deep sequencing to engineer the functional activity and specificity of TCRs on the surface of a human T cell line at high throughput. We applied TCR-Engine to successfully engineer synthetic TCRs for increased potency and specificity to a clinically relevant tumor-associated antigen (MAGE-A3) and validated their translational potential through multiple in vitro and in vivo assessments of safety and efficacy. Thus, TCR-Engine represents a valuable technology for engineering of safe and potent synthetic TCRs for immunotherapy applications.<br />Competing Interests: Declaration of interests ETH Zurich has filed for patent protection on the technology and sequences described herein, and R.V.-L., J.S.J., and S.T.R. are named as co-inventors on this patent (WO2021074249A1). R.V.-L and S.T.R. are co-founders and hold shares of Engimmune Therapeutics AG. S.T.R. may hold shares of Alloy Therapeutics. S.T.R. is on the scientific advisory board of Engimmune Therapeutics and Alloy Therapeutics.<br /> (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.) ) Array ( [Name] => SubjectMinor [Label] => Contributed Indexing [Group] => [Data] => <i>Keywords: </i>T cell receptor; TCR; deep sequencing; immunotherapy; protein engineering ) Array ( [Name] => NumberCAS [Label] => Substance Nomenclature [Group] => ID [Data] => 0 (Antigens, Neoplasm)<br />0 (Peptides)<br />0 (Receptors, Antigen, T-Cell) ) Array ( [Name] => DateEntry [Label] => Entry Date(s) [Group] => Date [Data] => <i>Date Created: </i>20220929 <i>Date Completed: </i>20221014 <i>Latest Revision: </i>20221018 ) Array ( [Name] => DateUpdate [Label] => Update Code [Group] => Date [Data] => 20221216 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1016/j.immuni.2022.09.004 ) Array ( [Name] => AN [Label] => PMID [Group] => ID [Data] => 36174557 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1016/j.immuni.2022.09.004
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[StartPage] => 1953
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Antigens, Neoplasm
[Type] => general
)
[1] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[2] => Array
(
[SubjectFull] => Immunotherapy
[Type] => general
)
[3] => Array
(
[SubjectFull] => Peptides
[Type] => general
)
[4] => Array
(
[SubjectFull] => Immunotherapy, Adoptive
[Type] => general
)
[5] => Array
(
[SubjectFull] => Receptors, Antigen, T-Cell
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity.
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Vazquez-Lombardi R
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jung JS
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Schlatter FS
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mei A
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mantuano NR
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bieberich F
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hong KL
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kucharczyk J
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kapetanovic E
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Aznauryan E
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Weber CR
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Zippelius A
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Läubli H
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Reddy ST
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 11
[M] => 10
[Text] => 2022 Oct 11
[Type] => published
[Y] => 2022
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-electronic
[Value] => 1097-4180
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 55
)
[1] => Array
(
[Type] => issue
[Value] => 10
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Immunity
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |